PDX Model Cohort
Sarcoma PDX Models
Advance your sarcoma therapeutic candidates using a tumor bank of rare and meticulously curated Sarcoma PDX Models directly established from late stage, metastatic and heavily pretreated patient tumors.
Summary
Champions Oncology offers 136* clinically relevant Sarcoma PDX models derived from patients with late-stage, metastatic, and heavily pretreated disease, many of whom received Standard of Care therapies. Of these, 68* models have been characterized through Next Generation Sequencing (WES and RNA-seq) and in vivo drug response testing, providing a robust and diverse dataset for evaluating biomarkers of response and non-response in this indication. More details on these models can be accessed via Champions’ Model Select®.
(*Model numbers fluctuate as our dataset continuously evolves.)
Champions' leading Sarcoma PDX Models cohort showcases primary models, each reflecting key clinical characteristics, mutations, and pretreatment history.
Access to the largest bank of Sarcoma PDX models with clinically relevant molecularand pathological characteristics on the market.
Most Sarcoma models were pretreated with standard of care therapies, including ifosfamide/eptoposide or cisplatin/gemcitabine combinations, and include models resistant to targeted treatments and advanced cancer therapies.
Access to highly characterized Sarcoma models with High Complexity Flow Cytometry, WES, RNAseq, Proteomics and Phosphoproteomics.
Clinically Relevant Models
Living & diverse bank of clinically relevant models that correlate with clinical outcomes
Pretreated PDX Models
Established from tumor biopsies from patients pretreated with latest generation therapies
Multi-omic Characterization
Clinical annotations coupled with molecular datasets and in vivo responses